After Goldman Sachs tossed cold water on the company's market-beating performance by initiating a sell recommendation today, shares in Valeant Pharmaceuticals (NYSE: VRX) lost 10.9% of their value today.Last year was a successful one for Joseph Papa, Valeant's CEO. Papa inherited a company struggling to overcome a host of challenges stemming from a relationship with its specialty distributor that proved to be all too close for comfort and a mountainous debt load his predecessor amassed.IMAGE SOURCE: GETTY IMAGES.Continue reading
Why Valeant Pharmaceuticals Tumbled 10.9% Today
newsfeedback@fool.com (Todd Campbell), The Motley Fool
Wed, 01/24/2018 - 5:48pm
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more